Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWJ1609 is an oral, tablet-based bowel-preparation combination developed by Daewoong Pharmaceutical for cleansing the colon before colonoscopy. It contains sodium sulfate, potassium sulfate, anhydrous magnesium sulfate, simethicone, and sodium picosulfate. The sulfate salts act as poorly absorbed osmotic laxatives that retain water in the intestinal lumen; sodium picosulfate provides a complementary stimulant-laxative effect after colonic activation; and simethicone reduces intraluminal foam. In a randomized multicenter Phase 3 study, the reduced-sulfate, sodium-picosulfate-containing formulation required 20 tablets and demonstrated non-inferior bowel-cleansing efficacy versus a conventional oral sulfate tablet preparation. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41695285/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DWJ1609.